Dr. Fernsten obtained a PhD in Immunology from Duke University. Dr. Fernsten has over 17 years of experience evaluating immunological responses to vaccines and biologics and served as Senior Director at Wyeth-Lederle Vaccines, Wyeth Vaccines Research, and Pfizer Vaccine Research. He has a broad background in vaccine research and development and contributed to numerous bacterial and viral vaccine programs, five of which (Prevnar®, Meningitec®, FluMist®, Prevnar 13®, Trumenba®) resulted in successful product launches. He has spearheaded the development of leading-edge assay technologies that were accepted by world health leaders in vaccines and biologics and recently established the successful serological evaluation of Prevnar 13® immunogenicity. Prior to joining Wyeth-Lederle Vaccines, Dr. Fernsten carried out basic research in cancer and autoimmunity at the Scripps Research Institute, The National Cancer Institute, and the University of North Carolina.